Previous Close | 0.0600 |
Open | 0.0550 |
Bid | 0.0500 x N/A |
Ask | 0.0600 x N/A |
Day's Range | 0.0500 - 0.0550 |
52 Week Range | 0.0300 - 0.3000 |
Volume | |
Avg. Volume | 102,493 |
Market Cap | 4.293M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0200 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Lophos Holdings Inc. (CSE: MESC) ("Lophos" or the "Company") proudly announces a milestone accomplishment from its subsidiary, Lophos Pharmaceuticals Corp. Specializing in the cultivation, research, and commercialization of peyote, the company has completed the propagation of an additional three thousand (3,000) seeds, marking a significant expansion of its cultivation efforts. Overview Lophos Pharmaceuticals Corp. completes the pla
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- Lophos Holdings Inc. (“Lophos” or the “Company”) (CSE:MESC) is delighted to announce the successful receipt of building occupancy for its subsidiary, Lophos Pharmaceuticals Corp., in Napanee, Ontario. This milestone achievement follows the dedicated efforts of Carmichael Engineering Ltd., the esteemed HVAC engineering and construction firm based in Belleville, ON, whose partnership has been integral to the project's conclusion. Carm
VANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. ("ThreeD"), a publicly traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, and Lophos Holdings Inc. ("Lophos"), have entered into a Securities Purchase Agreement ("Agreement") on April 12, 2024. Under the terms of the Agreement, Lophos will issue and sell 2,125,000 common shares (the "Purchased Lophos Shares") an